ACE inhibitors and calcium channel blockers: Patterns of use and associations with mortality in type 1 diabetes

Diabetes Research and Clinical Practice

Volumn 65, Issue 1, 2004, Pages 37-43

  Sobolewski, Brad A ^a   Zgibor, Janice C ^b   Orchard, Trevor J ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ACE inhibitors; Calcium channel blockers; Mortality; Type 1 diabetes

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; TREATMENT OUTCOME;

ADULT; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE;

EID: 2442438505     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2003.11.017     Document Type: Article

References (44)

1. American Diabetes Association, Standards of care for people with diabetes, Diabetes Care 24 (Suppl. 1) (2001) S33-S43.
2. Molitch M.E. ACE inhibitors and diabetic nephropathy. Diabetes Care. 17:1994;756-760
3. Gazis A., Page S.R., Cockcroftt J.R. ACE inhibitors, diabetes and cardiovascular disease. Diabetologia. 41(5):1998;595-597
4. Gerstein H.C. Cardiovascular and metabolic benefits of ACE inhibition. Diabetes Care. 23(7):2000;882-883
5. Francis G.S. ACE inhibition in cardiovascular disease. N. Engl. J. Med. 342(3):2000;201-202
6. Parving H.H. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J. Diabetes Complic. 10:1996;133-135
7. V.J. Dzau, Mechanism of protective effects of ACE inhibition on coronary artery disease, Eur. Heart J. (Suppl.) (1998) J:J2-6.
8. Arcaro G., Zenere B.M., Saggiani F., et al. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care. 9:1999;1536-1542
9. Chaturvedi N. HOPE and extension of indications for ACE inhibitors? Lancet. 355:2000;246-247
10. Bicket D.P. Using ACE inhibitors appropriately. Am. Family Phys. 66(3):2002;461-468
11. Blood Pressure Lowering Treatment Trialists' Collaboration, Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials, Lancet 356 (2000) 1955-1964.
12. Carella M.J., Gossain V.V., Jones J. The effects of a low-dose regimen of fosinopril on elevated urinary albumin excretion in normotensive type 1 diabetic patients. J. Med. 30(5-6):1999;305-320
13. Julius S., Majahalme S., Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. Am. J. Hypertens. 14(11 Pt 2):2001;301S-316S
14. Lewis J.B., Berl T., Bain R.P., Rhode R.D., Lewis E.J. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy: Collaborative Study Group. Am. J. Kidney Dis. 34(5):1999;809-817
15. Poulsen P.L., Ebbehoj E., Mogensen C.E. Lisinopril reduces albuminuria during exercise in low-grade microalbuminuric type 1 diabetic patients: a double blind study. J. Intern. Med. 249:2001;433-440
16. Yusuf S., Lonn E., Bosch J., et al. Summary of randomized trials of angiotensin converting enzyme inhibitors. Clin. Exp. Hypertens. 21(5-6):1999;835-845
17. Yusuf S., Sleight P., Pogue J., Bosch J., Davie R., Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3):2000;145-153
18. H.C. Gerstein, Diabetes and the HOPE study: implications for macrovascular and microvascular disease, Int. J. Clin. Pract. Suppl. (117) (2001) 8-12.
19. Bojestig M., Karlberg B.E., Lindstrom T., et al. Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care. 24(5):2001;919-924
20. The ATLANTIS Study Group, Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension, Diabetes Care 23 (12) (2000) 1823-1829.
21. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria: The Microalbuminuria Captopril Study Group, Diabetologia 39 (5) (1996) 587-593.
22. The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ADA) Study Group, Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria, Diabetes 50 (2001) 843-850.
23. Braun S. Safety of calcium channel blockers: perspective on the controversy. Cardiology. 88(Suppl. 3):1997;1-2
24. Dougall H.T., McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Safety. 15(2):1996;91-106
25. Ferrari R. Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists. Am. J. Cardiol. 77:1996;22D-25D
26. Goldbourt U., Behar S., Reicher-Ross H., et al. Early administration of nifedipine in suspected acute mycocardial infarction. Arch. Intern. Med. 153:1993;345-353
27. Opie L.H., Messerli F.H. Nifedipine and mortality: grave defects in the dossier. Circulation. 92(5):1995;1068-1073
28. Pahor M., Psaty B.M., Alderman M.H., et al. Health outcomes associated with calcium antagonists compared with other first line antihypertensive therapies: a meta-analysis of randomized control trials. Lancet. 356:2000;1949-1954
29. Psaty B.M., Heckbert S.R., Koepsell T.D., et al. The risk of myocardial infarction associated with antihypertensive drug therapies. J. Am. Med. Assoc. 274(8):1995;620-625
30. Zucchelli P. Calcium channel blockers in diabetic nephropathy - is there life after the ABCD trial? Nephrol. Dial. Transpl. 13:1998;1930-1933
31. Crepaldi G., Carta Q., Deferrari G. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care. 21(1):1998;104-110
32. Mimran A., Ribstein J. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases. Am. J. Hypertens. 7:1994;73S-81S
33. Sheinfel G.R., Bakris G.L. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am. J. Hypertens. 12:1999;80S-85S
34. Parving H.H., Homme E., Jensen B.R., Hansen H.P. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int. 60(1):2001;228-234
35. The ACE Inhibitors in Diabetic Nephropathy Trialist Group, Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data, Ann. Intern. Med. 134 (5) (2001) 370-379.
36. Mogensen C.E. Drug treatment for hypertensive patients in special situations: diabetes and hypertension. Clin. Exp. Hypertens. 21(5-6):1999;895-906
37. WHO collaborating center for drug statistics methodology, Anatomical Therapeutic Chemical (ATC) classification index with Defined Daily Doses (DDD).
38. DERI Study Group, International analysis of insulin diabetes dependent mortality: a preventable mortality perspective, Am. J. Public Health 142 (1995) 612-618.
39. De la Sierra A., Ruilope L.M. Treatment of hypertension in diabetes mellitus. Curr. Hypertens. Rep. 2(3):2000;335-342
40. O'Hare P., Bilbous R., Mitchell T., O'Callaghan C.J., Viberti G.C. The Ace-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects Study Group, Low dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care. 23(12):2000;1823-1829
41. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators, Lancet 355 (9200) (2000) 253-259.
42. Dunn E.J., Burton C.J., Feest T.G. The care of patients with diabetic nephropathy: audit, feedback, and improvement. Q. J. Med. 92(8):1999;443-449
43. Hemels M.E., Bennett H.A., Bonari L., Han D., Traverso M.L., Einarson T.R. HOPE study impact on ACE inhibitors use. Ann. Pharmacother. 37(5):2003;640-645
44. Tu K., Mamdan M.M., Jacka R.M., Ford N.J., Rothwell D.M., Tu J.V. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ. 168(5):2003;552-557